Kodiak Sciences (KOD) Net Income towards Common Stockholders (2017 - 2026)

Kodiak Sciences (KOD) reported Net Income towards Common Stockholders of -$58.1 million for Q1 2026, down 1.16% on a YoY basis from -$58.8 million in Q1 2025, and down 2.54% quarter-over-quarter from -$56.7 million in Q4 2025.

Kodiak Sciences (KOD) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Kodiak Sciences has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$58.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1.16% year-over-year to -$58.1 million; the trailing twelve-month figure through Mar 2026 stood at -$230.5 million (down 21.04% YoY), and the FY2025 full-year result was -$229.9 million, down 30.83% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$58.1 million, down from -$56.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$42.7 million in Q1 2024, with the low at -$95.7 million in Q1 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$62.3 million across 5 years, with a median of -$58.1 million in 2026.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 89.82% — and 2024, when it soared 43.82%.
  • Kodiak Sciences' Net Income towards Common Stockholders stood at -$71.1 million in 2022, then climbed by 16.29% to -$59.5 million in 2023, then grew by 25.94% to -$44.0 million in 2024, then slipped by 28.71% to -$56.7 million in 2025, then fell by 2.54% to -$58.1 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$58.1 million (Q1 2026), -$56.7 million (Q4 2025), and -$61.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -13.56 Mn
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -14.46 Mn
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - -3.63 Mn
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 1.03 Bn
9 Abivax 95.45 Bn 95.45 Bn - -56.48 Mn
10 Kodiak Sciences 1.92 Bn 1.92 Bn - -58.14 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -58.14 Mn
Dec 31, 2025 -56.70 Mn
Sep 30, 2025 -61.44 Mn
Jun 30, 2025 -54.27 Mn
Mar 31, 2025 -57.47 Mn
Dec 31, 2024 -44.05 Mn
Sep 30, 2024 -43.92 Mn
Jun 30, 2024 -45.03 Mn
Mar 31, 2024 -42.70 Mn
Dec 31, 2023 -59.48 Mn
Sep 30, 2023 -49.97 Mn
Jun 30, 2023 -80.15 Mn
Mar 31, 2023 -71.00 Mn
Dec 31, 2022 -71.05 Mn
Sep 30, 2022 -77.00 Mn
Jun 30, 2022 -90.58 Mn
Mar 31, 2022 -95.70 Mn
Dec 31, 2021 -93.05 Mn
Sep 30, 2021 -67.50 Mn
Jun 30, 2021 -55.83 Mn